The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

A Study of MK-3475A (Pembrolizumab Formulated With MK-5180) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT06041802
Recruitment Status : Recruiting
First Posted : September 18, 2023
Last Update Posted : April 22, 2024
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2, 2027
Estimated Study Completion Date : March 2, 2027